Celgene Corporation

Celgene — Merger or Acquisition (February 2019)

37 slides from Celgene's merger presentation, Feb 20, 2019

  1. Slide 1: Creating a Global BioPharma Leader

    & Bristol-Myers Squibb Creating a Global BioPharma Leader INVESTOR PRESENTATION FEBRUARY 2019

  2. Slide 2: Important Information for Investors and Stockholders

    Important Information for Investors and Stockholders ‘This communcaton dos not cnshtute an offer o sel cr he solctatin ofan offer o buy any secures or a slctaton of any voter approval It does not constiute a prospectus or prospectus quvaent coaiment No cfering of secures sal be made except by means

  3. Slide 3: Cautionary Statement Regarding Forward Looking Statements

    Cautionary Statement Regarding Forward Looking Statements

  4. Slide 4: Strategic Overview

    EEE Strategic Overview BMS has followed consistent and successful strategy for over 10 years: = Combine the strength and expertise of traditional pharma with agility and innovation of biotech — Focus on developing transformational medicines in areas of high unmet medical need — Underpinned by leadin

  5. Slide 5: Our Strategic Foundation

    Our Strategic Foundation <Sery BIOTECH PHARMA Diversified Specialty BioPharm Focused and Integrated INNOVATION The best PEOPLE helping patients in their fight against serious disease —— B® Bristol Myers Squib

  6. Slide 6: Our Strategy Has Delivered

    Our Strategy Has Delivered ‘ACTING FOR LONG-TERM SUCCESS BIOPHARMA STRATEGY EXITING PRIMARY CARE STRING OF PEARLS Belief in innovation Focusing on high-value opportunities Externally-sourced assets 10-Year EPS CAGR: 8% Continued Dividend Commitment + 10 Consecutive Annual Dividend Increases Opportun

  7. Slide 7: Strong Commercial Execution Across Key Brands

    Strong Commercial Execution Across Key Brands: 9% FY Revenue Growth in 2018 OPDIVO 6.75 €36% —SPRYCEL S208 - Eliquis. sean €) 32% vervovs 51.33 @ 7% (@pinaban) tablets . (ipiimumab) Son 52.78 09% Emplicit. so.238 €) 7% finales ® Bristol Myers Sous

  8. Slide 8: Strong Performance for BMS Immuno-Oncology

    Strong Performance for BMS Immuno-Oncology Business with Continued Growth Opportunities Strong Commercial Execution Advancing the Science in Immuno-oncology $8.1B 2018 Revenue >400 —foropano”™ 7 U.S, Indications in 4 years post launch ® Bristol Myers Sous

  9. Slide 9: Leading Cardiovascular Medicine with Significant Growth Potential

    EEE Leading Cardiovascular Medicine with Significant Growth Potential El iqu. iS. Best-in-class efficacy and safety profile in 3 Atrial-Fibrillation & VTE prevention apixaban G oe Leading oral anti-coagulant in the US $6.4B 32% Revenue Growth Leading global CV franchise Strong growth outlook as lead

  10. Slide 10: Celgene - Highly Complementary to BMS

    EEE Celgene - Highly Complementary to BMS » Premier commercial hematology business with industry-leading pipeline for sustained leadership * Commercial strength in dermatology with leading oral brand + Attractive late-stage & early-stage pipeline + Differentiated cell therapy platform + Leading capa

  11. Slide 11: Celgene Acquisition Fits Naturally Within BMS Strategy

    Celgene Acquisition Fits Naturally Within BMS Strategy Continued focus in core Creates new company _ Builds on legacy of disease areas of high with increased scale proactively executing for unmet medical need while maintaining long-term success focus and agility Celgene Pipeline — A bundled “String

  12. Slide 12: Creating a Leading Focused Biopharma Company

    EEE Creating a Leading Focused Biopharma Company LEADING DEEP AND BROAD ROBUST EARLY-STAGE FRANCHISES LATE-STAGE PIPELINE PIPELINE (PHASE 1/1 ASSETS) #4 ONCOLOGY: 10 / souD TUMORS 10 ne Onan ‘& HEMATOLOGY PHASEIN ——pgTENTIALNEW 21 Reva and ponays ASSETS PRODUCTLAUNCHES—_gucotocy: 9 Top 5 20+ 10/Soli

  13. Slide 13: Celgene Acquisition Financial Framework

    Celgene Acquisition Financial Framework Value Combined Company P&L y D High quality pipeline at attractive price Substantial cashflows reduce debt & improve credit profile in the next 2-3 years Expected to grow every year through 2025

  14. Slide 14: Celgene Pipeline Provides Significant Opportunity for Value Creation

    Celgene Pipeline Provides Significant Opportunity for Value Creation Marketed Pipeline Products ~$55B VALUE Synergies >$20B VALUE Substantial value above implied cost ® Bris Myers Squibb.

  15. Slide 15: Combined Company Projection: Continued Growth and Financial Strength

    Combined Company Projection: Continued Growth and Financial Strength PRO FORMA REVENUE* PRO FORMA NET INCOME (ron caan* Revenue. $8 Net income, $8 7) 5 +0 rc re) sis 0 0 ‘0 so s » Py 2019 2019 Bristol Myers Sub

  16. Slide 16: Combined Company Projection: Continued Growth and Financial Strength

    Combined Company Projection: Continued Growth and Financial Strength PRO FORMA CASH FLOW* PRO FORMA CREDIT PROFILE* Fcr.n8 Debi/EIDA $0 sis <2.5x . is : s » 20206 Bristol Myers Squibb

  17. Slide 17: Key Financial Assumptions

    EEE Key Financial Assumptions - Revlimid revenue modeled more conservatively relative to consensus + Pipeline contribution from each company is risk-adjusted + Stock-based compensation included in non-GAAP financials ® Bristol Myers Sous

  18. Slide 18: Revlimid IP Considerations

    EEE Revlimid IP Considerations Key focus of due diligence We believe bookend scenarios are unlikely Multiple outcomes based on litigation, IPR, settlement processes Our model is more conservative than consensus Significant cash flow enabling de-leveraging while delivering returns to shareholders On

  19. Slide 19: Financial Summary - A Compelling Transaction

    ee Financial Summary - A Compelling Transaction Conservative view on Revlimid revenue compared to consensus Transaction Creates Value Pipeline provides significant opportunity for value creation Continued P&L Growth Revenue and earnings growth through 2025 + Strengthened portfolio for post 2025+ per

  20. Slide 20: Combined Company: Future Growth Drivers

    Combined Company: Future Growth Drivers PRO FORMA REVENUE* + Eliquis growth in Atrial Fibrillation & VTE Revenue, $5 + 20+ potential new indications for oo Opdivo/Yervoy including in adjuvant « a - 6 potential launches in next two years a + 50 Ph 1/2 Assets to deliver next set of “ potential medicin

  21. Slide 21: Significant Long-term Growth Opportunities for Existing BMS Immuno-Oncology Franchise

    Significant Long-term Growth Opportunities for Existing BMS Immuno-Oncology Franchise 1L NSCLC ial (¢M-227 (Part 10) ‘cM-227 (Part 2) cM-9LA *Perclnkcatils.gov Expected "Timing 1H 2019 Mid 2019 2020 Adjuvant Tumor! Vial Melanoma cH-315 Bladder cH-274 Esophageal 577 Renal cH314 Lung cH816 Expected Ti

  22. Slide 22: Significant Long-term Growth Opportunities Additional to Immuno-Oncology and Eliquis

    Significant Long-term Growth Opportunities Additional to Immuno-Oncology and Eliquis Opportunity to launch 6 new medicines in next 2 years with >$15B non-risk-adjusted revenue potential First-and Best-in-clas novel anemia drug + 50 Phi/2 agents that will Potential tobe the frst & only mein for patie

  23. Slide 23: Luspatercept

    Luspatercept A First-in-Class EMA to Address Chronic Anemias Eyythroid Maturation Agent “EMA"~ ciiferentioted mechanism to EPO in eating chronic anemios MDS ‘~80k mild/int Myelodysplastic Syndrome patients with anemia tn US/EU + 2L RS+ Post EPO setting - limited treatment options today: Competing ef

  24. Slide 24: Fedratinib

    Fedratinib Potential first and only medicine for patients resistant/refractory to Jakafi High unmet medical need in EFFICACY (JAKARTA2 Trial) NDA recently (MF patients that fail or cannot submitted fo FDA, tolerate Jokatt By Fedratinib: of patents achieved Splenic volume reduction selective JAK2 of

  25. Slide 25: CAR-T: A New Frontier in Cancer Therapeutics

    EEE CART: A New Frontier in Cancer Therapeutics Transformational modality with unprecedented efficacy KEY SUCCESS DRIVERS + Clinical data demonstrates potential product differentiation + Leverage BMS world-class access & reimbursement + Clinical Profile, BMS access and Celgene hematology capability

  26. Slide 26: Liso-cel

    Liso-cel Potential Best-in-Class anti-CD19 CAR-T for B Cell Malignancies ‘Strong Efficacy & Potential Superior Safety Profile Broad Clinical Development Plan to Advance into Eatlier Lines and Additional Indications eicacy sare PHASE! PHASE! PIVOTAL "RANSCENO NICO} (PHISL¢ RR) WANSCEND WORD (P/U ad J

  27. Slide 27: Anti-BCMA CAR-T with transformational efficacy in late line RRMM

    bb2121 Anti-BCMA CAR-T with transformational efficacy in late line RRMM Sondordtecimen! Regimens merging 882121 Pole PHASE! PIVOTAL Sond “ey PHASE! — PHASEM PIVOT MULIPLE MYELOMA = Potential U.S. Approval 2H 2020 = > Be SG rrare sy, mas e211 I bng developed by Clr parterstp with Hebd Bo Brisk Myers

  28. Slide 28: Ozanimod

    EEE Ozanimod Selective $1P with potential to be Best-in-Class in relapsing form of MS and First-in-Class in Inflammatory Bowel Disease Relapsed Multiple Sclerosis Inflammatory Bowel Disease + Potential to improve on safety profile of existing + Promising efficacy and remission rates in S1P therapy P

  29. Slide 29: TYK2

    8... TYK2 Best-in-Class Oral with Biologic-like Efficacy ‘% ot patients who achieve PASI-75° Potential for Differentiated Profile: + Selective inhibition of TYK2 + Biologic ike eficacy based on Ph2 results — «Safety differentiate from JAKS | | ‘Opportunities for post-integration synergy: ner Pees +

  30. Slide 30: High Potential Agents and Pipeline Assets to Watch

    EEE High Potential Agents and Pipeline Assets to Watch ICARHi25 (BCMA CAR 7) cc-90002 (C047 Mab) (CART focused on RRM Phase 1 Study targeting NHL Randomaed Pace I stdin 2L Estimated pivotal study in 2019 Paneeate evaluating CSFIR+ Ne oF on ee ne Randomied Phase It Wal i Melanoma (NKTR214+Nvo vs No)

  31. Slide 31: Combination Leverages Leading Science & Innovation Platforms

    Combination Leverages Leading Science & Innovation Platforms Epigenetics ee Protein Homeostasis Biologics and Synthetic Biologics R&D Celi Therapies Ecosystem i Lathan Immunomodulatory ‘Agents ® Bris Myers Squibb.

  32. Slide 32: Pipeline Summary

    Pipeline Summary * 6 near-term product launches with five coming from Celgene + Leveraging BMS strength in commercial execution + Increased number of Ph1/2 assets will provide next ‘set of registrational medicines + Expanded set of scientific ns erm platforms and research capabilities for sustained

  33. Slide 33: BMS in 2025: Positioned for Continued Leadership

    EEE BMS in 2025: Positioned for Continued Leadership Positioned for Maturing Ph I/II Evolving Access & Pipeline Delivering Reimbursement Next Set of Broad, Balanced Landscape Registrational Assets & Earlier Life- Strength for Cycle Marketed Continued! Portfolio Investment in ‘Underpinned by cuting e

  34. Slide 34: The Right Deal at the Right Time

    EEE The Right Deal at the Right Time ‘Celgene NTM P/E Decined Overtime {Celgene Stock Closing Tracked Biotech Index Since Labor Day ote Oat BMS / Celgene Natural Exchange Ratio at Two Pre-Acquisition Celgene Analyst Price Targets Higher than Offer Price Sett ett sa? OT te ® Bristol Myers Sous

  35. Slide 35: Roadmap to Completion

    Roadmap to Completion Transaction remains on track to close in Q3 2019 “Transaction Preliminary registration | ‘BMS and Celgene special ‘announced “oint” proxy statement shareholders’ meetings filed with SEC scheduled to approve Timeline met ecian SEC review proce oftegitaton pin” pow sateen! Brisk

  36. Slide 36: Appendix

    Appendix Brisk Myers Squib

  37. Slide 37: Deep and Broad Combined Pipeline

    Deep and Broad Combined Pipeline Phase 1 Phase 1/1 a =a oncology: = ro Rakes ae —

Celgene — Merger or Acquisition (February 2019) on 6ix